Journal Article
. 2005 Dec;17(1).
doi: 10.1093/annonc/mdj022.

Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials

M Namer 1 P Fargeot  H Roché  M Campone  P Kerbrat  P Romestaing  A Monnier  E Luporsi  P Montcuquet  J Bonneterre  French Adjuvant Study Group  
Affiliations
  • PMID: 16361531
  •     7 citations

Abstract

Background: The purpose was to compare disease-free survival (DFS) between epirubicin-based chemoendocrine therapy and tamoxifen alone in one to three node-positive (N1-3), estrogen-receptor-positive (ER+), postmenopausal early breast cancer (EBC) patients.

Patients And Methods: We analyzed, retrospectively, 457 patients randomized in FASG 02 and 07 trials who received: tamoxifen alone (30 mg/day, 3 years); or FEC50 (fluorouracil 500 mg/m2, epirubicin 50 mg/m2, cyclophosphamide 500 mg/m2, six cycles every 21 days) plus tamoxifen started concurrently. Radiotherapy was delivered after the third cycle in FASG 02 trial, and after the sixth in FASG 07 trial.

Results: The 9-year DFS rates were 72% with tamoxifen and 84% with FEC50-tamoxifen (P = 0.008). The multivariate analysis showed that pathological tumor size >2 cm was an independent prognostic factor (P = 0.002), and treatment effects remained significantly in favor of chemoendocrine therapy (P = 0.0008). The 9-year overall survival rates were 78% and 86%, respectively (P = 0.11). In the multivariate model, there was a trend in favor of chemoendocrine therapy (P = 0.07).

Conclusion: The addition of FEC50 adjuvant chemotherapy to tamoxifen significantly improves long-term DFS in N1-3, ER+ and postmenopausal women. Chemoendocrine therapy seems to be more effective than tamoxifen in terms of long-term survival.

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
Olivia Pagani, Shari Gelber, +14 authors, International Breast Cancer Study Group.
Breast Cancer Res Treat, 2008 Oct 28; 116(3). PMID: 18953651    Free PMC article.
Is Chemoendocrine Treatment without Alternative?
Richard Greil.
Breast Care (Basel), 2008 Jan 01; 3(4). PMID: 21076602    Free PMC article.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
Davide Bedognetti, Mario Roberto Sertoli, +12 authors, Paolo Bruzzi.
J Natl Cancer Inst, 2011 Sep 17; 103(20). PMID: 21921285    Free PMC article.
Progress in adjuvant chemotherapy for breast cancer: an overview.
Jesus Anampa, Della Makower, Joseph A Sparano.
BMC Med, 2015 Aug 19; 13. PMID: 26278220    Free PMC article.
Highly Cited. Review.
Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
Sakshi Jasra, Jesus Anampa.
Curr Treat Options Oncol, 2018 May 13; 19(6). PMID: 29752560
Review.
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
Eleftherios P Mamounas, Christy A Russell, +2 authors, Kathy S Albain.
NPJ Breast Cancer, 2018 Aug 30; 4. PMID: 30155517    Free PMC article.
Review.